XML 72 R58.htm IDEA: XBRL DOCUMENT v3.10.0.1
Asset Acquisition and License Agreements - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Jun. 30, 2017
Dec. 31, 2016
Sep. 30, 2016
Dec. 31, 2015
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2010
Asset Acquisition [Line Items]                                
Restricted cash (SRX Cardio)         $ 1,062,000       $ 173,000       $ 1,062,000 $ 173,000    
Net Income (loss) attributable to noncontrolling interest (SRX Cardio)         (338,000) $ 126,000 $ 223,000 $ (332,000) 280,000 $ (5,000) $ 240,000 $ (45,000) (321,000) 470,000 $ 930,000  
Milestone payment on regulatory approval                           5,000,000    
Research and development expense                         216,205,000 203,701,000 246,854,000  
Millennium                                
Asset Acquisition [Line Items]                                
2019         600,000               600,000      
2020         600,000               600,000      
2021         600,000               600,000      
2022         600,000               600,000      
Thereafter         1,800,000               1,800,000      
Millennium | United States                                
Asset Acquisition [Line Items]                                
Milestone payment on regulatory approval $ 5,000,000                              
Millennium | Research and Development Expense                                
Asset Acquisition [Line Items]                                
Milestone payment   $ 2,000,000                            
Millennium | Cost of Sales | United States                                
Asset Acquisition [Line Items]                                
Finite-lived intangible assets, amortization expense                         600,000      
Astellas Pharma Inc                                
Asset Acquisition [Line Items]                                
Percentage required to pay for any payment received under collaboration excluding royalties                               20.00%
Research and development expense                         $ 0 800,000 1,800,000  
Maximum | Millennium                                
Asset Acquisition [Line Items]                                
Percentage of royalty on product sales                         8.00%      
Maximum | Astellas Pharma Inc                                
Asset Acquisition [Line Items]                                
Milestone payable on occurrence of specified events                               $ 71,500,000
Minimum | Millennium                                
Asset Acquisition [Line Items]                                
Percentage of royalty on product sales                         2.00%      
SRX Cardio                                
Asset Acquisition [Line Items]                                
Variable interest entity, Upfront payment     $ 2,200,000 $ 500,000                        
Variable interest entity, Terms of arrangements                         Accordingly, SRX Cardio is subject to consolidation and we have consolidated the financial statements of SRX Cardio by (a) eliminating all intercompany balances and transactions; and (b) allocating income or loss attributable to the noncontrolling interest in SRX Cardio to net income or loss attributable to noncontrolling interest in our consolidated statement of operations and reflecting noncontrolling interest on our consolidated balance sheet.      
Fair value of indefinite lived intangible assets         3,200,000               $ 3,200,000      
Noncontrolling interest in variable Interest entity         2,900,000               2,900,000      
Restricted cash (SRX Cardio)   $ 178,000     $ 30,000       $ 173,000       $ 30,000 $ 173,000 $ 178,000  
SRX Cardio | License Agreement                                
Asset Acquisition [Line Items]                                
Notice period for agreement termination     90 days                          
SRX Cardio | License Agreement | Maximum                                
Asset Acquisition [Line Items]                                
Research and development milestone payment obligation     $ 152,500,000                          
Percentage of royalties on worldwide net sales, obligated to pay     6.00%                          
SRX Cardio | License Agreement | Minimum                                
Asset Acquisition [Line Items]                                
Percentage of royalties on worldwide net sales, obligated to pay     2.00%